Clinical Trial: Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095023) titled 'Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer' on July 17.

Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Breast Cancers

Intervention: DRUG: Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab

Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral soluti...